Myopia is a refractive disorder caused by excessive axial elongation, leading to blurred distance vision. Its development involves genetic, environmental and molecular factors, including retinal N6-methyladenosine (m6A) RNA modification.
Another two biopharma companies priced IPOs on Nasdaq to raise a combined $350 million, becoming the fourth and fifth firms to debut on U.S. markets in 2026.
